Background about Glioblastoma Glioblastoma, GBM, is an aggressive and the most frequent malignant brain tumor primary brain tumor with poor prognosis. At diagnosis, the standard treatment is largely confined to…
The FDA has approved Retevmo capsules for the treatment of patients with lung cancer or thyroid cancer harboring RET alterations. This is the first therapy approved to target RET gene…
Background Patients with advanced or metastatic kidney cancer are a population that despite recent advances remains in need of additional therapeutic options that extend survival. The immunotherapy and tyrosine kinase…
"Compassionate drugs", also called “named patient drugs” or “early access drugs”. Compassionate drugs can be one of three cases: Compassionate drugs (1) - Can be an experimental, investigational drug that…
Chondrosarcoma and IDH1 - Background For locally advanced and/or metastatic Chondrosarcoma, no known effective therapy exists. The standard protocols are not effective. Mutations in the IDH1/2 enzymes occur in up…
Monica (not her real name), a 43-year-old Cyprus resident, was diagnosed with GBM brain cancer, Glioblastoma, two years ago. One year ago Monica's husband contacted us after she accepted and…
FDA may approve new biological drug called IMMU-132 for treating patients with triple negative breast cancer On a personal note "My mother died of triple-negative breast cancer. Her name was…
New Trial - Ovarian Cancer Data from the phase Ib study were made available as part of the virtual platform for the SGO 2020 Annual Meeting that has been implemented due…
What is the link between the corona virus and cancer? The world is experiencing an outbreak of a new betacoronavirus known as Severe Acute Respiratory Syndrome Corona Virus 2, SARS-CoV-2…
Published on March 10, 2020 Background The FDA granted Breakthrough Therapy designation to JNJ-61186372 (JNJ-6372) for the treatment of patients with Metastatic Non-Small Cell Lung Cancer, NSCLC, with EGFR exon…